

Atinivicitinib Formulation

Version 3.0 Revision Date: 14.04.2025 SDS Number: 6047696-00017 Date of last issue: 28.09.2024
Date of first issue: 19.06.2020

SECTION 1. IDENTIFICATION

Product name : Atinivicitinib Formulation

Manufacturer or supplier's details

Company : MSD

Address : Talcahuano 750, 6th floor, Ciudad Autonoma
Buenos Aires, Argentina C1013AAP

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 50 -< 70
atinivicitinib	2169273-59-8	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Atinivicitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages

Atinvcitinib Formulation

Version 3.0 Revision Date: 14.04.2025 SDS Number: 6047696-00017 Date of last issue: 28.09.2024
Date of first issue: 19.06.2020

cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	CMP	10 mg/m ³	AR OEL
		TWA	10 mg/m ³	ACGIH
atinvcitinib	2169273-59-8	TWA	80 ug/m ³ (OEB 3)	Internal
		Wipe limit	800 ug/100cm ²	Internal

Engineering measures : All engineering controls should be implemented by facility

Atinvcitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	off-white
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available

Atinvcitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	0,2 - 0,9 g/cm ³
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	May form explosive dust-air mixture during processing,

Atinvcitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

tions	handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Cellulose:**

Acute oral toxicity	: LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 5,8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	: LD50 (Rabbit): > 2.000 mg/kg

atinvcitinib:

Acute oral toxicity	: Assessment: The substance or mixture has no acute oral toxicity LD50 (Rat): > 2.000 mg/kg Assessment: The substance or mixture has no acute oral toxicity
Acute dermal toxicity	: LD50 Dermal (Rat, male): > 2.000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**atinvcitinib:**

Species	: human skin
Method	: in vitro skin corrosion test
Result	: No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Atinvcitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

Components:**atinvcitinib:**

Species	:	Bovine cornea
Result	:	No eye irritation
Method	:	in vitro eye irritation test
Remarks	:	No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**atinvcitinib:**

Test Type	:	Local lymph node assay (LLNA)
Routes of exposure	:	Dermal
Species	:	Mouse
Result	:	Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

atinvcitinib:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Micronucleus test Test system: Human lymphocytes Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral

Atinvcitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

	Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks
Result	: negative

atinvcitinib:

Remarks	: Not classified due to lack of data.
---------	---------------------------------------

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on fetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

atinvcitinib:

Effects on fertility	: Remarks: Not classified due to lack of data.
Effects on fetal development	: Test Type: Reproduction/Developmental toxicity screening test Species: Rat Application Route: Oral General Toxicity Maternal: NOAEL: 90 Teratogenicity: NOAEL: 90 Developmental Toxicity: NOAEL F1: 90

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Atinvcitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

Repeated dose toxicity**Components:****Cellulose:**

Species	: Rat
NOAEL	: ≥ 9.000 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

atinvcitinib:

Species	: Dog, male and female
NOAEL	: 6 mg/kg
Application Route	: Oral
Exposure time	: 6 Months
Number of exposures	: Daily

Species	: Rat, male and female
NOAEL	: 5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Number of exposures	: Daily

Species	: Rat, male and female
NOAEL	: 12 mg/kg
Application Route	: Dermal
Exposure time	: 3 Months
Number of exposures	: Daily

Aspiration toxicity

Not classified based on available information.

Components:**atinvcitinib:**

|| Not applicable

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	: LC50 (<i>Oryzias latipes</i> (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	--

atinvcitinib:

Toxicity to fish	: LC50 (<i>Pimephales promelas</i> (fathead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
------------------	---

Atinvcitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

	Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility. EC50 (Mysidopsis bahia (opossum shrimp)): > 100 mg/l Exposure time: 96 h Method: OPPTS 850.1500 Remarks: No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	: ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 100 mg/l End point: Growth Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility.
Toxicity to microorganisms	: EC10: > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition of activated sludge Method: OECD Test Guideline 209 EC50: > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition of activated sludge Method: OECD Test Guideline 209

Ecotoxicology Assessment

Acute aquatic toxicity	: No data available
Chronic aquatic toxicity	: No data available

Persistence and degradability**Components:****Cellulose:**

Biodegradability	: Result: Readily biodegradable.
------------------	----------------------------------

Bioaccumulative potential**Components:****atinvcitinib:**

Partition coefficient: n-octanol/water	: log Pow: 1,45
--	-----------------

Mobility in soil

No data available

Other adverse effects

No data available

Atinvcitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

The ingredients of this product are reported in the following inventories:

DSL : not determined

AICS : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date	:	14.04.2025
Date format	:	dd.mm.yyyy

Further information

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD

Atinivicitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

compile the Material Safety
Data SheeteChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
AR OEL	:	Argentina. Occupational Exposure Limits

ACGIH / TWA	:	8-hour, time-weighted average
AR OEL / CMP	:	TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Atinvcitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.0	14.04.2025	6047696-00017	Date of first issue: 19.06.2020

AR / Z8